XVARY Composite Score
56
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Greenwich LifeSciences is trying to stop breast cancer from coming back after surgery.
How it gets paid
Last year Greenwich Lifesci made n/a in revenue. GP2 clinical development was the main engine at $0.0M, or 100% of sales.
What just happened
FY 2024 EPS was -$1.21, worse than -$0.69 in 2023.
At a Glance
B balance sheet — gets the job done, barely
70/100 earnings predictability — reasonably predictable
-$1.21 fy2024 eps est
2.0% operating margin
1.15 beta
XVARY composite: 56/100 — below average
What They Do
Greenwich LifeSciences is trying to stop breast cancer from coming back after surgery.
Phase IIb trial (mid-stage human test) showed no recurrences after a median five years in the HER2/neu 3+ group (a breast-cancer marker). You are buying one idea, not a catalog. There are 4 employees and one lead program, so every data read matters.
How They Make Money
n/a
annual revenue
GP2 clinical development
$0.0M
Phase IIb data
$0.0M
Phase III preparation
$0.0M
Corporate overhead
$0.0M
The Products That Matter
Prevents cancer recurrence
GLSI-100 (GP2)
500+ patients enrolled
this is the whole company. it is the only clinical asset, and management said the Phase III program is screening over 800 patients a year.
single asset
Key Numbers
-$1.21
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
FY 2024 EPS was -$1.21, worse than -$0.69 in 2023.
The company is still pre-revenue. Q4 2024 was the weakest quarter in the table at -$0.62 per share, versus -$0.20 a year earlier.
$1.21
eps
2.0%
operating margin
n/a
n/a
the number that mattered
The number that mattered was -$1.21. Losses widened from -$0.69 in 2023 to -$1.21 in 2024.
source: company filings, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk here is Phase III failure for GP2. This company has one late-stage asset, no revenue, and a $370M valuation resting on the same clinical readout.
Med
Phase III trial failure
GLSI-100 is the whole story. If the trial fails, there is no second act sitting behind it.
Impact: most of the $370M market cap is exposed to one clinical outcome.
Med
Cash burn and dilution
The company reported a $15.8M net loss, held $12.5M in cash, and burned $9.5M annually. If the study runs longer than expected, new capital likely arrives before new revenue.
Impact: more shares outstanding can reduce your upside even if the science stays on track.
Med
Better-funded competitors move faster
A November 2025 competitive analysis called MacroGenics the clear winner because it was further along and more de-risked. In biotech, being right later is sometimes the same as being wrong.
Impact: even a good asset can lose strategic value if competing programs become the preferred option first.
A forced capital raise or a weak trial update would hit a company with no revenue, a thin float, and a valuation built almost entirely on GP2.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Catalyst
FLAMINGO-01 enrollment pace
The company said screening moved above 800 patients a year in March 2026. Faster screening is not just good optics — it is how you shorten the wait for the number that matters.
Financing
Cash runway into 2027
With $12.5M in cash against a $9.5M annual burn, you should read every update through one lens: does current cash still get the company where it says it is going.
Float
Post-lock-up selling pressure
The insider lock-up extends through September 2026. After that, even modest selling can matter because the float is restricted and liquidity is thin.
Science
Whether GP2 keeps its edge
The company is a one-program story, and a 2025 analysis already framed MacroGenics as more mature and more de-risked. If competing data gets stronger, the market will notice before approval decisions do.
Analyst Rankings
earnings predictability
70 / 100
For a pre-revenue biotech, 70/100 is unusually steady. In human-speak, analysts think the losses are fairly visible even if the stock is not.
risk rank
2
This ranking says the balance sheet is not in immediate distress. It does not mean the clinical outcome is safe.
Source: institutional data
Institutional Activity
institutional ownership data for GLSI is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$32
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive